Evidence map›Paper›PMID 38283164›Full record

ArticleProceedings. IEEE International Conference on Healthcare Informatics2023

Named Entity Recognition and Normalization for Alzheimer's Disease Eligibility Criteria.

Zenan Sun, Cui Tao

Open access · greenAbstract read
In one paragraph

Article in Proceedings. IEEE International Conference on Healthcare Informatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zenan SunSchool of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, Texas.
Cui TaoSchool of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, Texas.
The University of Texas Health Science Center · US

Funding

Facilitate Observational Studies of Alzheimer's Disease and Alzheimer's Disease-Related Dementias Using Ontology and Natural Language ProcessingRF1AG072799 · NIA · YALE UNIVERSITY · PI LIU, HONGFANG, TAO, CUI · 2021 to 2021
$2.4M
Facilitate Observational Studies of Alzheimer's Disease and Alzheimer's Disease-Related Dementias Using Ontology and Natural Language ProcessingR01AG072799 · NIA · YALE UNIVERSITY · PI HONGFANG LIU, Cui Tao · 2025 to 2026
$1.7M
CICADA: clinical informatics and computational approaches for drug-repositioning of AD/ADRDR56AG074604 · NIA · UNIVERSITY OF PENNSYLVANIA · PI CHEN, YONG, TAO, CUI · 2021 to 2022
$1.5M
NIA NIH HHS R01 AG072799NIA NIH HHS R56 AG074604NIA NIH HHS RF1 AG072799
6 · The paper itself

Abstract

Alzheimer's Disease (AD) is a complex neurodegenerative disorder that affects millions of people worldwide. Finding effective treatments for this disease is crucial. Clinical trials play an essential role in developing and testing new treatments for AD. However, identifying eligible participants can be challenging, time-consuming, and costly. In recent years, the development of natural language processing (NLP) techniques, specifically named entity recognition (NER) and named entity normalization (NEN), have helped to automate the identification and extraction of relevant information from the eligibility criteria (EC) more efficiently, in order to facilitate semi-automatic patient recruitment and enable data FAIRness for clinical trial data. Nevertheless, most current biomedical NER models only provide annotations for a restricted set of entity types that may not be applicable to the clinical trial data. Additionally, accurately performing NEN on entities that are negated using a negative prefix currently lacks established techniques. In this paper, we introduce a pipeline designed for information extraction from AD clinical trial EC, which involves preprocessing of the EC data, clinical NER, and biomedical NEN to Unified Medical Language System (UMLS). Our NER model can identify named entities in seven pre-defined categories, while our NEN model employs a combination of exact match and partial match search strategies, as well as customized rules to accurately normalize entities with negative prefixes. To evaluate the performance of our pipeline, we measured the precision, recall, and F1 score for the NER component, and we manually reviewed the top five mapping results produced by the NEN component. Our evaluation of the pipeline's performance revealed that it can successfully normalize named entities in clinical trial ECs with optimal accuracies. The NER component achieved a overall F1 of 0.816, demonstrating its ability to accurately identify seven types of named entities in clinical text. The NEN component of the pipeline also demonstrated impressive performance, with customized rules and a combination of exact and partial match strategies leading to an accuracy of 0.940 for normalized entities.

Indexed as

Alzheimer’s Diseaseclinical trial eligibility criterianamed entity normalizationnamed entity recognition

Identifiers

PMID38283164
PMCPMC10815931
OpenAlexW4389543618

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.